Researchers at the UCLA Jonsson Comprehensive Cancer Center have confirmed that a large number of genetic variants of unknown significance are in fact verified mutations that predispose patients to a rare hereditary syndrome that increases the risk of kidney cancer.
FDA fast tracks Alladapt’s multi-food allergy immunotherapy
Share this article Alladapt’s ADP101 is being investigated as a mono- and multi-food allergy oral immunotherapy in patients aged 4-17 years. Image Credit: Ground Picture
November 23, 2023